<div id="readability-page-1"><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. </li><li> Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off </li></ul>Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) just unveiled an announcement. Biocytogen Pharmaceuticals has established an Audit Committee under its board of directors to enhance corporate governance. This committee is responsible for reviewing financial disclosures, supervising audit work, and ensuring effective internal controls, thereby replacing the need for a board of supervisors. The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page. More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Biocytogen Pharmaceuticals (Beijing) Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is incorporated in the People’s Republic of China and is listed on the Hong Kong Stock Exchange. Average Trading Volume: 523,150 Technical Sentiment Signal: Buy Current Market Cap: HK$12.78B For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.</div>

688796

Biocytogen Pharmaceuticals has established an Audit Committee under its board of directors to enhance corporate governance. This committee will review financial disclosures, supervise audit work, and ensure effective internal controls, replacing the need for a board of supervisors.

Biocytogen Pharmaceuticals Enhances Governance with New Audit Committee